ReviewJournal of immunology research2017
Genetically Modified T-Cell-Based Adoptive Immunotherapy in Hematological Malignancies.
Review in Journal of immunology research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The Emerging World of TCR-T Cell Trials Against Cancer: A Systematic Review.Technology in cancer research & treatment · 2019Pooled it
- Low-dose IL-2 Ameliorates Experimental Autoimmune Myasthenia Gravis in Rats by Restoring the CD4-positive Helper T-cell Balance Via the JAK/STAT5 Pathway.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2026Article
- Research Progress of Multicomponent Co-Loaded Nanomedicine Delivery Systems for Tumor Immunotherapy.International journal of nanomedicine · 2026Review
- Targeting immune microenvironment in cervical cancer: current research and advances.Journal of translational medicine · 2025Review
- Expanding the Horizons of CAR-T Cell Therapy: A Review of Therapeutic Targets Across Diverse Diseases.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Article
- Characteristics of tumor microenvironment and novel immunotherapeutic strategies for non-small cell lung cancer.Journal of the National Cancer Center · 2022Review
- Neoantigen-specific TCR-T cell-based immunotherapy for acute myeloid leukemia.Experimental hematology & oncology · 2022Review
- Research advance in lipid nanoparticle-mRNA delivery system and its application in CAR-T cell therapy.Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2022Review
- Nanotechnology in cervical cancer immunotherapy: Therapeutic vaccines and adoptive cell therapy.Frontiers in pharmacology · 2022Review
- The Potential of Tissue-Resident Memory T Cells for Adoptive Immunotherapy against Cancer.Cells · 2021Review
- Overview of Cellular Immunotherapies within Transfusion Medicine for the Treatment of Malignant Diseases.International journal of molecular sciences · 2021Review
- Engineered TCR-T Cell Immunotherapy in Anticancer Precision Medicine: Pros and Cons.Frontiers in immunology · 2021Review
- Noninvasive Imaging of Cancer Immunotherapy.Nanotheranostics · 2021Review
- 3D Immunocompetent Organ-on-a-Chip Models.Small methods · 2020Article
- Impact and Intricacies of Bone Marrow Microenvironment in B-cell Lymphomas: From Biology to Therapy.International journal of molecular sciences · 2020Review
- Chimeric Antigen Receptor T Cell Exhaustion during Treatment for Hematological Malignancies.BioMed research international · 2020Review
- ANCA-Associated Vasculitides and Hematologic Malignancies: Lessons from the Past and Future Perspectives.Journal of immunology research · 2019Review
- Engineering chimeric antigen receptor-T cells for cancer treatment.Molecular cancer · 2018Review
- Evaluating natural killer cell cytotoxicity against solid tumors using a microfluidic model.OncoimmunologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A significant proportion of hematological malignancies remain limited in treatment options. Immune system modulation serves as a promising therapeutic approach to eliminate malignant cells. Cytotoxic T lymphocytes (CTLs) play a central role in antitumor immunity; unfortunately, nonspecific approaches for targeted recognition of tumor cells by CTLs to mediate tumor immune evasion in hematological malignancies imply multiple mechanisms, which may or may not be clinically relevant. Recently, genetically modified T-cell-based adoptive immunotherapy approaches, including chimeric antigen receptor (CAR) T-cell therapy and engineered T-cell receptor (TCR) T-cell therapy, promise to overcome immune evasion by redirecting the specificity of CTLs to tumor cells. In clinic trials, CAR-T-cell- and TCR-T-cell-based adoptive immunotherapy have produced encouraging clinical outcomes, thereby demonstrating their therapeutic potential in mitigating tumor development. The purpose of the present review is to (1) provide a detailed overview of the multiple mechanisms for immune evasion related with T-cell-based therapies; (2) provide a current summary of the applications of CAR-T-cell- as well as neoantigen-specific TCR-T-cell-based adoptive immunotherapy and routes taken to overcome immune evasion; and (3) evaluate alternative approaches targeting immune evasion
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.